Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2008; 51:2422-2429, doi:10.1016/j.jacc.2008.01.069
© 2008 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mega, J. L.
Right arrow Articles by Sabatine, M. S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mega, J. L.
Right arrow Articles by Sabatine, M. S.
Related Collections
Right arrowRelated Article

Thrombus Precursor Protein and Clinical Outcomes in Patients With Acute Coronary Syndromes

Jessica L. Mega, MD, MPH*,*, David A. Morrow, MD, MPH, FACC*, James A. de Lemos, MD, FACC{dagger}, Satishkumar Mohanavelu, MS*, Christopher P. Cannon, MD, FACC* and Marc S. Sabatine, MD, MPH, FACC*

* TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts
{dagger} Division of Cardiology, Department of Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas.


Figure 1
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Fibrin Formation

Formation of fibrin and identification of thrombus precursor protein (TpP). D = D-domain; E = E-domain.

 

Figure 2
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Cumulative Incidence of the Composite Outcome by TpP Level

Cumulative incidence of the composite outcome (death, myocardial infarction, ischemia requiring revascularization, or ischemia requiring rehospitalization) through 10 months stratified by TpP levels ≤ median (8.9 µg/ml) or > median. CI = confidence interval; HR = hazard ratio; TpP = thrombus precursor protein.

 

Figure 3
View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Rates of Death or MI by TpP Level

Nelson-Aalen event rates through 10 months for death or myocardial infarction for patients with TpP levels ≤ median (8.9 µg/ml) or > median. MI = myocardial infarction; other abbreviations as in Figure 2.

 

Figure 4
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Hazard Ratios for the Composite Outcome in Subgroups by TpP Level

Hazard ratio plot for the risk of the composite outcome (death, myocardial infarction, ischemia requiring revascularization, or ischemia requiring rehospitalization) with a TpP > median (8.9 µg/ml) in specified subgroups. The p value to test for interaction was >0.18 for all subgroups. CAD = coronary artery disease; CI = confidence interval; LMWH = low molecular weight heparin; NSTEMI-UA = non–ST-segment elevation myocardial infarction–unstable angina; STEMI = ST-segment elevation myocardial infarction; SX = symptoms; TpP = thrombus precursor protein; TX = treatment; UFH = unfractionated heparin.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement